Last reviewed · How we verify
TQ-B3139
TQ-B3139 is a Tyrosine kinase inhibitor Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. It is currently in Phase 3 development for Solid tumors (specific indications under investigation in Phase 3).
TQ-B3139 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival.
TQ-B3139 is a small molecule being studied as a potential treatment for various types of cancer, including non-small cell lung cancer and advanced solid tumors. It is being investigated in a clinical trial, NCT04398940, in combination with crizotinib for MET-altered advanced non-small cell lung cancer.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TQ-B3139 |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Tyrosine kinase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TQ-B3139 inhibits receptor tyrosine kinases and intracellular signaling pathways critical for tumor growth. The drug is designed to block multiple oncogenic pathways simultaneously, potentially providing broader anti-tumor activity. It is being developed by Chia Tai Tianqing Pharmaceutical Group as an oral small-molecule therapeutic.
Approved indications
- Solid tumors (specific indications under investigation in Phase 3)
Common side effects
Key clinical trials
- Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules (PHASE1)
- A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer (PHASE2)
- Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (PHASE2)
- Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQ-B3139 CI brief — competitive landscape report
- TQ-B3139 updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI
Frequently asked questions about TQ-B3139
What is TQ-B3139?
How does TQ-B3139 work?
What is TQ-B3139 used for?
Who makes TQ-B3139?
What drug class is TQ-B3139 in?
What development phase is TQ-B3139 in?
Related
- Drug class: All Tyrosine kinase inhibitor drugs
- Manufacturer: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Solid tumors (specific indications under investigation in Phase 3)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing